for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Epizyme Inc

EPZM.OQ

Latest Trade

3.37USD

Change

-0.25(-6.91%)

Volume

468,045

Today's Range

3.30

 - 

3.56

52 Week Range

3.30

 - 

14.30

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.62
Open
3.51
Volume
468,045
3M AVG Volume
18.80
Today's High
3.56
Today's Low
3.30
52 Week High
14.30
52 Week Low
3.30
Shares Out (MIL)
103.90
Market Cap (MIL)
376.10
Forward P/E
-1.51
Dividend (Yield %)
--

Next Event

Q4 2021 Epizyme Inc Earnings Release

Latest Developments

More

Epizyme Reports Third Quarter 2021 Financial Results

Epizyme Receives Fast Track Designation From U.S. FDA

Epizyme Announces CEO Succession

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Epizyme Inc

Epizyme, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization epigenetic treatment for people with cancer and other serious diseases. The Company’s lead product candidate TAZVERIK (tazemetostat) is an oral selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT). AZVERIK is available to the eligible patients and their physicians in the United States through a specialty distribution network. The Company is developing tazemetostat for the treatment of a range of cancer types in multiple treatment settings. Tazemetostat is a pipeline product, which is showing clinical activity as an investigational monotherapy in multiple cancer indications.

Industry

Biotechnology & Drugs

Contact Info

400 Technology Sq Ste 4

CAMBRIDGE, MA

02139-3584

United States

+1.617.2295872

http://www.epizyme.com/

Executive Leadership

David M. Mott

Independent Chairman of the Board

Grant C. Bogle

President, Chief Executive Officer, Chief Financial Officer, Director

Shefali Agarwal

Executive Vice President, Chief Medical and Development Officer

Jeffery L. Kutok

Chief Scientific Officer

Vicki Vakiener

Chief Commercial Officer

Key Stats

2.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-1.720

2019

-1.930

2020

-2.290

2021(E)

-2.405
Price To Earnings (TTM)
--
Price To Sales (TTM)
10.99
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1,507.38
LT Debt To Equity (MRQ)
1,507.38
Return on Investment (TTM)
-84.07
Return on Equity (TTM)
-74.70

Latest News

Latest News

BRIEF-Epizyme To Present Data From Tazemetostat Clinical Program During 2020 ASCO Virtual Scientific Program

* EPIZYME TO PRESENT DATA FROM TAZEMETOSTAT CLINICAL PROGRAM DURING THE 2020 ASCO VIRTUAL SCIENTIFIC PROGRAM Source text for Eikon: Further company coverage:

BRIEF-Epizyme Posts Q1 Loss Per Share Of $0.51

* EPIZYME REPORTS BUSINESS PROGRESS AND FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Epizyme Appoints Jeffery Kutok As Chief Scientific Officer

* EPIZYME APPOINTS JEFFERY KUTOK, M.D., PH.D., AS CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage:

BRIEF-Epizyme Reports Fourth Quarter Loss Per Share Of $0.59

* EPIZYME PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Epizyme Announces FDA Acceptance Of NDA For Filing With Priority Review For Tazverik (Tazemetostat) For The Treatment Of Follicular Lymphoma

* EPIZYME ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR FILING WITH PRIORITY REVIEW FOR TAZVERIK™ (TAZEMETOSTAT) FOR THE TREATMENT OF FOLLICULAR LYMPHOMA

Epizyme prices rare tissue cancer treatment at $15,500 a month

Epizyme Inc on Thursday priced its treatment for a ultra rare, slow growing type of cancer that affects soft tissue at $15,500 per month after getting an approval from the U.S. Food and Drug Administration.

FDA approves Epizyme's treatment for rare tissue cancer

The U.S. Food and Drug Administration has approved Epizyme Inc's treatment for a rare, slow growing type of cancer that affects the soft tissue, the company said on Thursday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up